To the editor
We commend the authors on their comprehensive review investigating the use of vitamin D supplementation across many clinical outcomes.1 However, we disagree with their conclusions that the current literature supports only a beneficial effect of vitamin D supplementation on fracture risk. As the authors correctly point out, observational studies of vitamin D are subject to important limitations since, in general, a decreased level of vitamin D is a marker of poor health. Consequently, bias due to confounding is likely to be an important limitation of observational vitamin D studies. Further, since many diseases lead to a decrease in time outside and reduced sun exposure, reverse causation may likewise plague such studies. While randomized controlled trials (RCT) are usually less susceptible to these forms of bias, vitamin D is off-patent. Therefore RCTs of vitamin D supplementation are often small and limited to short follow-up periods, due to cost constraints.
Given this lack of high-quality observational and RCT evidence, we elected to investigate whether vitamin D influences the risk of MS and coronary artery disease (CAD) using Mendelian randomization (MR). This approach allows for an assessment of lifelong exposure to decreased vitamin D on risk of disease that is uninfluenced by reverse causation and less susceptible to bias due to confounding. This is because MR uses the genetic determinants of vitamin D status as proxies for vitamin D level and since genetic variants are randomized at meiosis, MR retains many of the advantages of an RCT. While our MR analyses supported a causal role of vitamin D in the MS etiology (OR = 2.02, 95 % CI = 1.65–2.46, p = 7.72 × 10−12),2 they did not support an important effect of vitamin D on CAD risk (OR = 0.99, 95 % CI = 0.84–1.17, p = 0.93).3
We concluded that vitamin D supplementation may be an important form of primary prevention for MS, which warrants further investigation by clinical trials. Restricting a systematic review of the effects of vitamin D to observational studies and RCTs ignores relevant information provided by MR. As this field progresses, we believe that a discussion of MR analyses in future reviews of vitamin D is worth consideration. Given the paucity of high-quality RCT data, MR may present the best evidence to support, or contradict, a role for vitamin D in disease susceptibility.
References
Allan GM, Cranston L, Lindblad A, et al. Vitamin D: a narrative review examining the evidence for ten beliefs. J Gen Intern Med. 2016;31:780–791. doi:10.1007/s11606-016-3645-y.
Mokry LE, Ross S, Ahmad OS, et al. Vitamin D and risk of multiple sclerosis: a Mendelian randomization study. PLoS Med. 2015;12:e1001866.
Manousaki D, Mokry LE, Ross S, et al. Mendelian randomization studies do not support a role for Vitamin D in coronary artery disease. Circ Genet. 2016.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mokry, L.E., Richards, J.B. Vitamin D: Ten Beliefs. J GEN INTERN MED 31, 1276 (2016). https://doi.org/10.1007/s11606-016-3817-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11606-016-3817-9